SCHEMBL1448280

SCHEMBL1448280

C[C@H](C(=O)O)c1ccc2cc(O)ccc2c1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 13/20 0.65
AKR1C2 P52895 13/20 0.65
PTGS2 P35354 4/20 0.65
PTGS1 P23219 3/20 0.65
CDC42 P60953 1/20 0.65
RAC1 P63000 1/20 0.65
CYP1A2 P05177 1/20 0.65
TSHR P16473 1/20 0.65
SLC22A6 Q4U2R8 1/20 0.65
AKR1B1 P15121 1/20 0.54
CYP2C9 P11712 2/20 0.53
HSD17B10 Q99714 1/20 0.53
APP P05067 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL134150 1.00 AKR1C3 (0.65) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL29993492 1.00 AKR1C3 (0.65) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL554068 1.00 AKR1C3 (0.65) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL29993475 1.00 AKR1C3 (0.65) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL13810650 0.89 AKR1C3 (0.53) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL12744140 0.88 AKR1C3 (0.51) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL11470486 0.85 AKR1C3 (0.69) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL10025981 0.83 AKR1B1 (0.69) AKR1C3AKR1C2PTGS2PTGS1CDC42
SCHEMBL1217681 0.83 AKR1B1 (0.69) AKR1C3AKR1C2PTGS2PTGS1CDC42
Ammonia Solution, Strong SCHEMBL11721423 0.83 AKR1C3 (0.67) AKR1C3AKR1C2PTGS2PTGS1CDC42

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115322099-B Naproxen-cinnamic acid derivative and application thereof in preparation of medicines for treating LPS-induced inflammation 五邑大学 2024-04-02 CN claimed
CN-115322099-A Naproxen-cinnamic acid derivatives and application thereof in preparation of drugs for treating LPS (LPS) -induced inflammation 五邑大学 2022-11-11 CN claimed
US-6740256-B1 COMPOSED OF THE COMPOUND OF (N,N'-DIETHYL (S)-2-(6-(4-(4'-ALKOXYPHENYL)BENZOYLOXY)-2-NAPHTHYL)PROPANAMIDE CHUNGHWA PICTURE TUBES, LTD. (TW) 2004-05-25 US claimed
JP-2053819-A None JP disclosed
JP-3031393-A None JP disclosed
EP-3160514-B1 CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING REILEY PHARMACEUTICALS INC (US) 2024-07-31 EP disclosed
US-20240190790-A1 CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING REILEY PHARMACEUTICALS INC (US) 2024-06-13 US disclosed
CN-115322099-B Naproxen-cinnamic acid derivative and application thereof in preparation of medicines for treating LPS-induced inflammation 五邑大学 2024-04-02 CN disclosed
US-11912664-B2 Determining small molecule-protein and protein-protein interactions PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-02-27 US disclosed
EP-3892610-B1 SULFUR (VI) FLUORIDE COMPOUNDS AND THEIR USE IN CLICK-REACTION SCRIPPS RESEARCH INST (US) 2023-08-16 EP disclosed
US-20230039244-A1 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME UNIV PENNSYLVANIA (US) 2023-02-09 US disclosed
JP-H0331393-A LIQUID CRYSTAL POLYMER COMPOSITION CONTAINING OPTICAL ACTIVE GROUP TOSOH CORP 1991-02-12 JP disclosed
US-4960892-A ENZYME INHIBITOR AMERICAN HOME PRODUCTS CORPORATION (US) 1990-10-02 US disclosed
EP-0301813-B1 NAPHTHALENEPROPIONIC ACID DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1990-08-08 EP disclosed
US-4937373-A Substituted naphthalene carboxylic acids HOFFMANN-LA ROCHE INC. (US) 1990-06-26 US disclosed
JP-H0253819-A LIQUID CRYSTALLINE POLYESTER CONTAINING OPTICALLY ACTIVE GROUP TOSOH CORP 1990-02-22 JP disclosed
EP-0301813-A1 Naphthalenepropionic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1989-02-01 EP disclosed
EP-0227078-A1 Process for preparing (S)-alpha-methylarylacetic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1987-07-01 EP disclosed
EP-0110671-B1 PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND PRECURSORS THEREOF SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1986-05-21 EP disclosed
EP-0110671-A1 Preparation of optically active alpha-arylalkanoic acids and precursors thereof SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1984-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039244-A1 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME AKR1C3, AKR1C2, AKR1A1 AKR1C3 1/4885AKR1C2 2/4885PTGS2 261/4885
US-20240190790-A1 CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING PTGES3, PTGES, HPGDS AKR1C3 568/4885AKR1C2 1264/4885PTGS2 6/4885
US-11912664-B2 Determining small molecule-protein and protein-protein interactions MAX, IK, CRYAA AKR1C3 4555/4885AKR1C2 4503/4885PTGS2 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.